| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
|
Sydes, M.R.
|
|
|
29 |
5 |
p. 1235-1248
|
article
|
| 2 |
Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis
|
Uno, H.
|
|
|
29 |
5 |
p. 1092-1094
|
article
|
| 3 |
Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma
|
Makita, S.
|
|
|
29 |
5 |
p. 1086-1089
|
article
|
| 4 |
Circulating tumor DNA detection in hepatocellular carcinoma
|
Cabel, L.
|
|
|
29 |
5 |
p. 1094-1096
|
article
|
| 5 |
CMS-dependent prognostic impact of KRAS and BRAF V600E mutations in primary colorectal cancer
|
Smeby, J.
|
|
|
29 |
5 |
p. 1227-1234
|
article
|
| 6 |
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
|
Rodríguez-Ruiz, M.E.
|
|
|
29 |
5 |
p. 1312-1319
|
article
|
| 7 |
Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay
|
Gage, M.M.
|
|
|
29 |
5 |
p. 1280-1285
|
article
|
| 8 |
Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?
|
Montagut, C.
|
|
|
29 |
5 |
p. 1083-1084
|
article
|
| 9 |
Editorial board
|
|
|
|
29 |
5 |
p. ii-iii
|
article
|
| 10 |
Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations
|
Taniguchi, Y.
|
|
|
29 |
5 |
p. 1331-1333
|
article
|
| 11 |
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
|
Kang, Y.-K.
|
|
|
29 |
5 |
p. 1220-1226
|
article
|
| 12 |
Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale
|
Masuishi, T.
|
|
|
29 |
5 |
p. 1330-1331
|
article
|
| 13 |
Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing
|
Nauta, I.H.
|
|
|
29 |
5 |
p. 1273-1279
|
article
|
| 14 |
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
|
Kommoss, S.
|
|
|
29 |
5 |
p. 1180-1188
|
article
|
| 15 |
Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study
|
Ng, C.K.Y.
|
|
|
29 |
5 |
p. 1286-1291
|
article
|
| 16 |
HPV status, like politics, is local—evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancer
|
Orosco, R.K.
|
|
|
29 |
5 |
p. 1089-1090
|
article
|
| 17 |
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
|
Haddad, R.I.
|
|
|
29 |
5 |
p. 1130-1140
|
article
|
| 18 |
It is time to rethink weight loss in cancer
|
Currow, D.C.
|
|
|
29 |
5 |
p. 1091-1092
|
article
|
| 19 |
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time
|
Pasello, G.
|
|
|
29 |
5 |
p. 1258-1265
|
article
|
| 20 |
Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review
|
Iacoboni, G.
|
|
|
29 |
5 |
p. 1120-1129
|
article
|
| 21 |
Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?
|
Creutzberg, C.L.
|
|
|
29 |
5 |
p. 1081-1082
|
article
|
| 22 |
MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer
|
Rose, A.M.
|
|
|
29 |
5 |
p. 1292-1303
|
article
|
| 23 |
Nivolumab combined with ruxolitinib: antagonism or synergy?
|
Debureaux, P.E.
|
|
|
29 |
5 |
p. 1334-1335
|
article
|
| 24 |
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
|
Jurczak, W.
|
|
|
29 |
5 |
p. 1266-1272
|
article
|
| 25 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
|
Italiano, A.
|
|
|
29 |
5 |
p. 1304-1311
|
article
|
| 26 |
Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis
|
Benke, I.N.
|
|
|
29 |
5 |
p. 1154-1179
|
article
|
| 27 |
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
|
Piccirillo, M.C.
|
|
|
29 |
5 |
p. 1189-1194
|
article
|
| 28 |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
|
Cruz, C.
|
|
|
29 |
5 |
p. 1203-1210
|
article
|
| 29 |
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane
|
Martin, M.
|
|
|
29 |
5 |
p. 1195-1202
|
article
|
| 30 |
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
|
Bachet, J.B.
|
|
|
29 |
5 |
p. 1211-1219
|
article
|
| 31 |
Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al.
|
Cherny, N.I.
|
|
|
29 |
5 |
p. 1335-1338
|
article
|
| 32 |
Restoration of conformation of mutant p53
|
Green, J.A.
|
|
|
29 |
5 |
p. 1325-1328
|
article
|
| 33 |
Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
|
Geffen, D.B.
|
|
|
29 |
5 |
p. 1096-1098
|
article
|
| 34 |
Should de-escalation of bone-targeting agents be standard of care?
|
Awan, A.
|
|
|
29 |
5 |
p. 1333-1334
|
article
|
| 35 |
Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis
|
Liu, C.
|
|
|
29 |
5 |
p. 1329-1330
|
article
|
| 36 |
Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials
|
de van der Schueren, M.A.E.
|
|
|
29 |
5 |
p. 1141-1153
|
article
|
| 37 |
Table of Contents
|
|
|
|
29 |
5 |
p. iv-vii
|
article
|
| 38 |
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
|
Siena, S.
|
|
|
29 |
5 |
p. 1108-1119
|
article
|
| 39 |
The case for ‘successfully’ treating hormone naïve metastatic prostate cancer
|
Efstathiou, E.
|
|
|
29 |
5 |
p. 1084-1086
|
article
|
| 40 |
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
|
Sobrero, A.
|
|
|
29 |
5 |
p. 1099-1107
|
article
|
| 41 |
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer
|
Liang, F.
|
|
|
29 |
5 |
p. 1320-1324
|
article
|
| 42 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
|
Vale, C.L.
|
|
|
29 |
5 |
p. 1249-1257
|
article
|
| 43 |
When is crossover desirable in cancer drug trials and when is it problematic?
|
Haslam, A.
|
|
|
29 |
5 |
p. 1079-1081
|
article
|
Journal description